BNP 105
Alternative Names: BNP-105Latest Information Update: 27 Feb 2024
At a glance
- Originator EMS
- Class Antiulcers
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Aphthous stomatitis
Most Recent Events
- 22 Jan 2024 Phase-I clinical trials in Aphthous stomatitis (In volunteers, In adolescents, In adults, In the elderly) in Brazil (PO) (NCT05772338)
- 16 Mar 2023 EMS plans to initiate a clinical trial to evaluate the efficacy and safety of BNP 105 in aphthous stomatitis in female participants (Recurrent, In volunteers, In adolescent, In adults, In the elderly) in Brazil (PO, Suspension) in October 2023 (NCT05772338)
- 16 Mar 2023 Preclinical trials in Aphthous stomatitis in Brazil (PO) (NCT05772338)